Iovance Biotherapeutics, Inc. (IOVA)
IOVA moved a median of +0.11% 30 minutes after news, and 0.00% by the close. How IOVA actually reacts to news — the realized, point-in-time move the market made, measured across 1,135 labeled events over the last three years with zero look-ahead.
IOVA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 1,128 |
| 30-min | +0.11% | 51% | 1,129 |
| 60-min | +0.16% | 52% | 1,129 |
| to close | 0.00% | 48% | 1,129 |
| Middle 50% of IOVA reactions | -1.12% to +1.96% |
|---|---|
| Median reaction (30-min) | +0.11% |
| Measured reactions | 1,135 |
Half of all Iovance Biotherapeutics, Inc. news events land between -1.12% and +1.96% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IOVA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | +0.29% | 50% | +0.25% |
| Analyst downgrades | 14 | -2.04% | 21% | +3.74% |
| Rating reiterations | 77 | -0.57% | 34% | +0.43% |
| Price-target raises | 12 | +0.02% | 50% | -3.41% |
| Price-target cuts | 22 | -0.78% | 36% | -0.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how IOVA ranks against every other measured name →
That’s how IOVA usually reacts — get an email when it moves on news →Email me when IOVA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IOVA's baseline. Nothing else.
Recent IOVA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | — | — | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | -8.80% | |
| Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | Press release | GlobeNewswire | +1.12% | -3.20% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | +12.98% | |
| Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million | Press release | GlobeNewswire | +1.02% | +12.98% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.53% | -2.02% | |
| Iovance Biotherapeutics to Present at Upcoming Conferences | Press release | GlobeNewswire | -0.18% | +0.57% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.98% | -0.12% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.19% | +4.72% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -2.19% | +4.72% | |
| Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | Press release | GlobeNewswire | -2.19% | +4.72% | |
| Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 | Press release | GlobeNewswire | +2.21% | +3.53% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.00% | +0.40% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +2.44% | -2.56% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.64% | +3.57% | |
| Form S-3ASR IOVANCE BIOTHERAPEUTICS, | SEC filing · Form S-3ASR | SEC EDGAR | +0.64% | +3.57% | |
| Form S-8 IOVANCE BIOTHERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +0.64% | +3.57% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.19% | +5.04% | |
| Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | Press release | GlobeNewswire | +2.07% | +13.77% | |
| Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 | Press release | GlobeNewswire | -1.09% | -3.65% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.73% | +0.24% | |
| Iovance Biotherapeutics to Present at Upcoming Conference | Press release | GlobeNewswire | +0.43% | +5.71% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +9.26% | +1.14% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +9.26% | +1.14% | |
| Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates | Press release | GlobeNewswire | +9.26% | +1.14% | |
| Form ARS IOVANCE BIOTHERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +4.18% | +11.92% | |
| Form DEF 14A IOVANCE BIOTHERAPEUTICS, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -1.26% | -1.78% | |
| Form DEFA14A IOVANCE BIOTHERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -1.26% | -1.78% | |
| Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 | Press release | GlobeNewswire | +0.14% | -0.29% | |
| Form PRE 14A IOVANCE BIOTHERAPEUTICS, For: Jun 10 | SEC filing · Form PRE | SEC EDGAR | -0.93% | +0.80% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.93% | +0.80% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | -1.89% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.69% | -1.89% | |
| Iovance Biotherapeutics to Present at Upcoming Conferences | Press release | GlobeNewswire | -3.53% | -0.79% | |
| Form 10-K IOVANCE BIOTHERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.09% | +8.93% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +4.12% | +15.24% | |
| Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas | Press release | GlobeNewswire | +4.12% | +15.24% | |
| Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates | Press release | GlobeNewswire | +4.12% | +15.24% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.45% | +0.70% | |
| Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 | Press release | GlobeNewswire | -0.75% | -5.26% | |
| Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma | Press release | GlobeNewswire | +2.69% | +4.54% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.66% | +7.96% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.94% | -7.55% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.02% | +12.10% | |
| Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.29% | +7.76% | |
| Form S-8 IOVANCE BIOTHERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | -0.40% | — | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.44% | +2.21% | |
| Form 8-K IOVANCE BIOTHERAPEUTICS, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.44% | +2.21% | |
| Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results | Press release | GlobeNewswire | -0.44% | +2.21% | |
| Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | Press release | GlobeNewswire | -0.47% | -9.30% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IOVA section they belong to.
Where else IOVA is measured.
IOVA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EXPRESS SCRIPTS (ESRX) | 1,137 | +0.02% | 51% |
| Neovasc Inc. - Common Shares (NVCN) | 1,136 | -0.47% | 37% |
| iRhythm Holdings, Inc. (IRTC) | 1,114 | -0.12% | 46% |
| GENOMIC HEALTH (GHDX) | 1,111 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Iovance Biotherapeutics, Inc.'s median reaction calculated?
Every labeled IOVA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,135 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of IOVA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IOVA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.